Norbert Mészáros1, Tibor Major2, Gábor Stelczer2, Zoltán Zaka2, Emőke Mózsa2,3, Dávid Pukancsik4, Zoltán Takácsi-Nagy2, János Fodor2, Csaba Polgár2. 1. Center of Radiotherapy, National Institute of Oncology, Ráth György u. 7-9, 1122, Budapest, Hungary. meszarosnorbert@oncol.hu. 2. Center of Radiotherapy, National Institute of Oncology, Ráth György u. 7-9, 1122, Budapest, Hungary. 3. Department of Radiooncology and Radiotherapy, Landesklinikum, Wiener Neustadt, Austria. 4. Department of Breast and Sarcoma Surgery, National Institute of Oncology, Budapest, Hungary.
Abstract
PURPOSE: To report 3‑year results of accelerated partial breast irradiation (APBI) using image-guided intensity-modulated radiotherapy (IG-IMRT) following breast conserving surgery (BCS) for low-risk early invasive breast cancer. PATIENTS AND METHODS: Between July 2011 and March 2014, 60 patients with low-risk early invasive breast cancer underwent BCS and were enrolled in this phase II prospective study. The total dose was 36.9 Gy (9 fractions of 4.1 Gy, two fractions/day). Patient setup errors were detected in LAT, LONG and VERT directions. Local tumour control, survival results, early and late side effects and cosmetic outcome were assessed. RESULTS: At a median follow-up of 39 months, all patients were alive and neither locoregional nor distant failure occurred. One contralateral breast cancer and two new primary malignancies outside the breast were observed. No grade (G) 3-4 acute toxicity was detected. G1 and G2 erythema occurred in 21 (35%) and 2 (3.3%) patients, respectively; while G1 oedema was observed in 23 (38.8%) cases. G1 and G2 pain was reported by 6 (10%) and 2 (3.3%) patients, respectively. Among the late radiation side effects, G1 pigmentation or telangiectasia, G1 fibrosis and G1 asymptomatic fat necrosis occurred in 10 (16.7%), 7 (11.7%) and 3 (5%) patients, respectively. No ≥ G2 late toxicity was detected. Cosmetic outcome was excellent in 43 (71.7%) and good in 17 (28.3%) patients. CONCLUSION: IG-IMRT is a reproducible and feasible technique for delivery of external beam APBI following BCS for treatment of low-risk, early-stage invasive breast carcinoma. In order to avoid toxicity, image guidance performed before each radiation fraction is necessary to minimize the PTV. Three-year results are promising, early and late radiation side-effects are minimal, and cosmetic results are excellent to good.
PURPOSE: To report 3‑year results of accelerated partial breast irradiation (APBI) using image-guided intensity-modulated radiotherapy (IG-IMRT) following breast conserving surgery (BCS) for low-risk early invasive breast cancer. PATIENTS AND METHODS: Between July 2011 and March 2014, 60 patients with low-risk early invasive breast cancer underwent BCS and were enrolled in this phase II prospective study. The total dose was 36.9 Gy (9 fractions of 4.1 Gy, two fractions/day). Patient setup errors were detected in LAT, LONG and VERT directions. Local tumour control, survival results, early and late side effects and cosmetic outcome were assessed. RESULTS: At a median follow-up of 39 months, all patients were alive and neither locoregional nor distant failure occurred. One contralateral breast cancer and two new primary malignancies outside the breast were observed. No grade (G) 3-4 acute toxicity was detected. G1 and G2 erythema occurred in 21 (35%) and 2 (3.3%) patients, respectively; while G1 oedema was observed in 23 (38.8%) cases. G1 and G2 pain was reported by 6 (10%) and 2 (3.3%) patients, respectively. Among the late radiation side effects, G1 pigmentation or telangiectasia, G1 fibrosis and G1 asymptomatic fat necrosis occurred in 10 (16.7%), 7 (11.7%) and 3 (5%) patients, respectively. No ≥ G2 late toxicity was detected. Cosmetic outcome was excellent in 43 (71.7%) and good in 17 (28.3%) patients. CONCLUSION: IG-IMRT is a reproducible and feasible technique for delivery of external beam APBI following BCS for treatment of low-risk, early-stage invasive breast carcinoma. In order to avoid toxicity, image guidance performed before each radiation fraction is necessary to minimize the PTV. Three-year results are promising, early and late radiation side-effects are minimal, and cosmetic results are excellent to good.
Entities:
Keywords:
APBI; Breast cancer; Image-guided; Intensity modulated; Toxicity
Authors: Alan A Lewin; Robert Derhagopian; Kunal Saigal; Joseph E Panoff; Andre Abitbol; D Jay Wieczorek; Vivek Mishra; Isildinha Reis; Annapoorna Ferrell; Lourdes Moreno; Cristiane Takita Journal: Int J Radiat Oncol Biol Phys Date: 2011-06-02 Impact factor: 7.038
Authors: Ivo A Olivotto; Timothy J Whelan; Sameer Parpia; Do-Hoon Kim; Tanya Berrang; Pauline T Truong; Iwa Kong; Brandy Cochrane; Alan Nichol; Isabelle Roy; Isabelle Germain; Mohamed Akra; Melanie Reed; Anthony Fyles; Theresa Trotter; Francisco Perera; Wayne Beckham; Mark N Levine; Jim A Julian Journal: J Clin Oncol Date: 2013-07-08 Impact factor: 44.544
Authors: Vratislav Strnad; Guido Hildebrandt; Richard Pötter; Josef Hammer; Marion Hindemith; Alexandra Resch; Kurt Spiegl; Michael Lotter; Wolfgang Uter; Mayada Bani; Rolf-Dieter Kortmann; Matthias W Beckmann; Rainer Fietkau; Oliver J Ott Journal: Int J Radiat Oncol Biol Phys Date: 2010-06-03 Impact factor: 7.038
Authors: Reshma Jagsi; Merav A Ben-David; Jean M Moran; Robin B Marsh; Kent A Griffith; James A Hayman; Lori J Pierce Journal: Int J Radiat Oncol Biol Phys Date: 2010-01-01 Impact factor: 7.038
Authors: Ursula Hille-Betz; Bernhard Vaske; Michael Bremer; Philipp Soergel; Sudip Kundu; Rüdiger Klapdor; Peter Hillemanns; Christoph Henkenberens Journal: Strahlenther Onkol Date: 2015-09-28 Impact factor: 3.621
Authors: Jayant S Vaidya; Frederik Wenz; Max Bulsara; Jeffrey S Tobias; David J Joseph; Mohammed Keshtgar; Henrik L Flyger; Samuele Massarut; Michael Alvarado; Christobel Saunders; Wolfgang Eiermann; Marinos Metaxas; Elena Sperk; Marc Sütterlin; Douglas Brown; Laura Esserman; Mario Roncadin; Alastair Thompson; John A Dewar; Helle M R Holtveg; Steffi Pigorsch; Mary Falzon; Eleanor Harris; April Matthews; Chris Brew-Graves; Ingrid Potyka; Tammy Corica; Norman R Williams; Michael Baum Journal: Lancet Date: 2013-11-11 Impact factor: 79.321
Authors: Csaba Polgár; Zsuzsanna Kahán; Olivera Ivanov; Martin Chorváth; Andrea Ligačová; András Csejtei; Gabriella Gábor; László Landherr; László Mangel; Árpád Mayer; János Fodor Journal: Pathol Oncol Res Date: 2022-06-23 Impact factor: 2.874
Authors: Norbert Mészáros; Tibor Major; Gábor Stelczer; Levente Jánváry; Zoltán Zaka; Dávid Pukancsik; Zoltán Takácsi-Nagy; János Fodor Md; Csaba Polgár Journal: Breast Date: 2020-10-30 Impact factor: 4.380